Astellas Pharma Inc.’s early 2018 buyout of Universal Cells Inc. (UC) may have laid the groundwork for longer-range steps in allogeneic CAR T-cell therapy, but Xyphos Biosciences Inc. CEO James Knighton told BioWorld that the buyout of his firm provides the Tokyo-based giant for now with “an incredibly elegant solution that has tremendous potential.” Read More
The stock at Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH), after an especially rough Thursday, began healing a bit as investors took in the company’s decision to stop dosing and enrolling patients in its phase IIb Catalyst trials. Read More
BEIJING – China is aggressively pushing its goal to make drugs more affordable, and foreign pharma giants are adjusting their pricing strategy for a market that comprises nearly 20% of the world’s population and is expected to continue growing. Read More
“Bacteria often only do harm at certain concentrations,” Stefan Kaufmann told BioWorld. In fact, bacteria have evolved an entire communication system, so-called quorum sensing, to monitor how many of their colleagues are in the vicinity, and then switch from growth to virulence only at high densities.? Read More
Throughout the year we have published the views of company executives, government regulators, industry analysts and scientists on a variety of topics and, in our popular annual feature, we include a selection of these that paints a picture of the significant events that shaped 2019. Read More
Scientists at the University of Tuebingen have identified a network of antifibrotic RNAs, and showed that this network was controlled by the transcription factor Pparg. Fibrosis, which is essentially the formation of inappropriate scar tissue, contributes to multiple diseases, and its molecular mechanisms are poorly understood. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations. Read More
